Are We Overtreating DCIS?

The conditional marketing approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma is based on data from the phase 1/2 EPCORE NHL-1 study.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Investigators of the phase 3 CheckMate-77T trial report positive findings for patients with nonmetastatic non–small cell lung cancer who were treated with neoadjuvant nivolumab and chemotherapy.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Monique Gary, DO, MSc, FACS, discusses emerging data on early-onset cancers, including breast cancer which had the highest incidence in this population.

The agent, which is a recombinant Erwinia asparaginase or crisantaspase, can be given to those with acute lymphoblastic leukemia and lymphoblastic lymphoma intravenously and intramuscularly.